Biopharma Market Update

Stifel

Research

77 Pages

Stifel reviews the state of the biopharma market amid volatile valuations, capital scarcity, and shifting M&A dynamics. Despite a 35% rebound in the XBI biotech index since early 2024, funding conditions remain selective, favoring late-stage or de-risked assets while early-stage firms continue to struggle.

Key Takeaways

Capital recovery: Global biopharma equity issuance reached $25.6 billion YTD, up 42% year over year, yet remains less than half of 2021’s peak.
Valuation landscape: The median EV-to-revenue multiple for commercial-stage biotechs stands at 4.7x, compared to 9.3x in 2021, signaling ongoing normalization.
M&A momentum: 2025 has seen 63 announced transactions exceeding $75 billion in value, with oncology, CNS, and metabolic diseases driving 70% of deal volume.
VIEW FULL REPORT

Join our newsletter to have all of this content + Exclusive Newsletter Bonus Content delivered to your inbox every week

Related Content

Markets
February
Feb 2026
Markets
Valuing AI: Extreme Bubble, New Golden Era, or Both?
Feb 2026
Markets
CFA Institute – Stocks for the Long Run Revisited: Dividends and “The Return Nobody Got”
Feb 2026

The information contained in this communication is of a general nature for informational purposes only, and does not constitute financial, investment, tax or legal advice. The information contained within this communication reflects the opinions of those referenced herein, and do not reflect the opinions of The Idea Farm, L.P. and its affiliates. Such opinions expressed herein are as of the date of production and are subject to change at any time without notice due to various factors, including changing market conditions or tax laws. Where data or information prepared by third parties is presented, no representation, warranty, or undertaking, expressed or implied, is given to the accuracy or completeness of such information by The Idea Farm, L.P. or any other person. While such sources are believed to be reliable, The Idea Farm, L.P. does not assume any responsibility for the accuracy or completeness of such information and does not undertake any obligation to update the information contained herein as of any future date. Any links to third party websites are offered only for use at your own discretion. The Idea Farm L.P., and its affiliates, are separate and unaffiliated from any third parties listed herein and are not responsible for their products, services, policies or the content of their website. All investments are subject to varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy or product referenced directly or indirectly in this communication will be profitable, perform equally to any corresponding indicated historical performance level(s), or be suitable for your portfolio. Past performance is not an indicator of future results.

Scroll to Top